Mount Yale Investment Advisors’s Vaxcyte PCVX Stock Holding History

Mount Yale Investment Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-639	Closed	-$20.8K	–	1335
2025 Q2	$20.8K	Buy	+639	New	+$20.9K	﹤0.01%	1034
2024 Q4	–	Sell	-4,000	Closed	-$457K	–	602
2024 Q3	$457K	Sell	4,000 -971	-20%	-$87.5K	0.04%	362
2024 Q2	$375K	Sell	4,971 -33	-0.7%	-$2.25K	0.03%	393
2024 Q1	$342K	Sell	5,004 -3,204	-39%	-$222K	0.03%	419
2023 Q4	$515K	Buy	8,208 +62	+0.8%	+$3.22K	0.05%	313
2023 Q3	$415K	Sell	8,146 -11	-0.1%	-$543	0.05%	333
2023 Q2	$407K	Buy	+8,157	New	+$387K	0.04%	337

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Mount Yale Investment Advisors's PCVX Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 639 shares — an estimated $20.8K sold.

Mount Yale Investment Advisors first reported a position in PCVX in Q2 2023 and held it in 7 quarters. The position peaked at $515K in Q4 2023. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

Mount Yale Investment Advisors reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
Mount Yale Investment Advisors sold 639 Vaxcyte shares in Q3 2025, an estimated $20.8K.
Mount Yale Investment Advisors first reported a position in Vaxcyte in Q2 2023 and held it in 7 quarters.
Mount Yale Investment Advisors's Vaxcyte position peaked at $515K in Q4 2023.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.